Status:
RECRUITING
Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer
Lead Sponsor:
IRCCS San Raffaele
Conditions:
Clear Cell Renal Cell Carcinoma
VHL Syndrome
Eligibility:
All Genders
18-99 years
Brief Summary
The goal of this study is to comprehensively map intra and inter tumor heterogeneity of ccRCC in VHL patients through the use of imaging, molecular biology and genomics techniques.
Detailed Description
It was hypothesized that the high intra- inter-tumor heterogeneity of sporadic ccRCC also defines VHL-ccRCCs, including different lesions within individual patients, and it was assumed that decoding V...
Eligibility Criteria
Inclusion
- VHL syndrome
- Presence of at least 3 kidney tumors larger that 3cm to be surgically removed
Exclusion
- Absence of VHL
- Quantity of kidney tumors \< 3
- Absence of surgery performance
Key Trial Info
Start Date :
November 8 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT06195150
Start Date
November 8 2023
End Date
October 31 2025
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Ospedale San Raffaele
Milan, MI, Italy, 20132